Someone might take on a license for either DEP® Irinotecan and DEP® Cabazitaxel but given they both need 'further investigation' it won't be for the lofty prices floated about on here over the years ... I guess if someone paid $5 million for each and agreed to absorb all the additional study costs it would be something in the interim and considered a small win in the scheme of things ?
@antibotter 's estimates of $100 million for each DEP® drug ( Post #:65156161 ) was always ambitious pie in the sky predictions IMO and as we now know from the recent company business update, all DEP® Docetaxel business development has been "paused" so it is a dead duck.
It truly is amazing how after all the grandstanding about how the DEP® phase 2 trials supposedly demonstrated 'proof of concept' and/or 'the science is so good' Starpharma appear to be begging regional pharma's now for any contribution to take the DEP® drugs further as big pharma are giving us the cold shoulder (not interested) ?
I also find it interesting that Starpharma are suggesting in this comment below.....
"many regional and country-centric companies have shared a greater interest in partnering at an earlier stage"
....... that the likes of Merck (a multinational company) aren't interested in phase 2 assets or phase 2 assets requiring further investigation (early stage assets) ? Here's one of the numerous examples of our supposed partner Merck's early moves on a phase 1 / 2a asset .....so sadly one might deduce it is not the phase of the asset that is the issue here but perhaps the data / results of our DEP® drugs aren't as great as we thought ?
https://www.fiercebiotech.com/biote...vision-new-opthalmology-assets-3b-eyebioo-buy
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
Restoret has already been tested in a phase 1b/2a trial called AMARONE in DME and neovascular age-related macular degeneration. The phase 2b/3 test is slated to begin in the second half of this year.
Extract from Starpharma ASX Business Update 22 May 2024
![]()
- Forums
- ASX - By Stock
- SPL
- Slow death
Slow death, page-25
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
|
|||||
Last
9.1¢ |
Change
-0.001(0.55%) |
Mkt cap ! $37.52M |
Open | High | Low | Value | Volume |
9.0¢ | 9.1¢ | 9.0¢ | $47.58K | 525.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 9.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.2¢ | 22000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 49413 | 0.091 |
1 | 2750 | 0.090 |
2 | 97420 | 0.089 |
1 | 5000 | 0.088 |
1 | 73255 | 0.087 |
Price($) | Vol. | No. |
---|---|---|
0.092 | 22000 | 1 |
0.093 | 30790 | 3 |
0.094 | 106393 | 1 |
0.099 | 1285 | 1 |
0.100 | 112106 | 4 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
SPL (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online